US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CITIUS ONCOLOGY INC

0.8101

+0.06018.01%

Pre-market: 0.7875-0.0226-2.79%04:00 EDT

Volume:134.13K

Turnover:102.58K

Market Cap:75.32M

PE:-1.64

High:0.8180

Open:0.7050

Low:0.7050

Close:0.7500

52wk High:2.25

52wk Low:0.4912

Shares:92.98M

Float Shares:18.20M

Volume Ratio:2.96

T/O Rate:0.74%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4931

EPS(LYR):-0.3380

ROE:-126.58%

ROA:-29.12%

PB:1.87

PE(LYR):-2.40

Loading ...

Overview Company News Filings

Citius Oncology Files Form 3 for Director Jonathan Peri

Citius Oncology Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate

Benzinga Earnings

Citius Oncology FY26 Q3 Net Loss Widens to $8.9 Million; Revenue Rises to $1.5 Million

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Press Release: Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Oncology Appoints Jonathan Peri as Independent Director, Expands Board to Nine Members

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

THOMSON REUTERS

Citius Oncology Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview

Citius Pharma Subsidiary Citius Oncology Says New Lymphir Institutional Accounts Jump 78% Q/Q

Citius Oncology Reports Strong Commercial Momentum for Its Cancer Treatment

THOMSON REUTERS

Citius Oncology provides update on commercial launch of Lymphir

Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO

Citius Oncology highlights Phase 1 study data for LYMPHIR-pembrolizumab combo in recurrent gynecologic cancers

Citius Oncology shareholders OK stock issuance tied to USD 25 million loan conversion option

Citius Oncology to present Phase 1 LYMPHIR-pembrolizumab combo data at ASCO 2026

Citius Oncology files draft information statement on warrant, loan conversion share issuance

Citius Oncology Inc reports results for the quarter ended March 31 - Earnings Summary

Citius Oncology FY26 Q2 net loss widens to $26.6 million; revenue rises to $1.7 million

Press Release: Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/CTOR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CTOR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":0.8101,"timestamp":1787688000000,"preClose":0.75,"halted":0,"volume":134132,"hourTrading":{"tag":"盘前","latestPrice":0.7875,"preClose":0.8101,"latestTime":"04:00 EDT","volume":3,"amount":2.3625,"timestamp":1787731210523,"change":-0.0226,"changeRate":-0.027898,"amplitude":0},"delay":0,"changeRate":0.08013333333333339,"floatShares":18204800,"shares":92981204,"eps":-0.493118,"marketStatus":"Pre-Mkt","change":0.0601,"latestTime":"08-26 05:31:14 EDT","open":0.705,"high":0.818,"low":0.705,"amount":102577.5945452,"amplitude":0.150667,"askPrice":1.07,"askSize":200,"bidPrice":0.75,"bidSize":1070,"shortable":3,"etf":0,"ttmEps":-0.493118,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787751000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8101,"preHourTrading":{"tag":"盘前","latestPrice":0.7875,"preClose":0.8101,"latestTime":"04:00 EDT","volume":3,"amount":2.3625,"timestamp":1787731210523,"change":-0.0226,"changeRate":-0.027898,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.7601,"preClose":0.8101,"latestTime":"19:35 EDT","volume":517,"amount":393.5492,"timestamp":1787700929927,"change":-0.05,"changeRate":-0.061721,"amplitude":0.061721},"volumeRatio":2.955083207155116},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","floatShares":18204800,"roa":"-29.12%","roe":"-126.58%","lyrEps":-0.337956,"volumeRatio":2.955083207155116,"shares":92981204,"dividePrice":0,"high":0.818,"amplitude":0.150667,"preClose":0.75,"low":0.705,"week52Low":0.4912,"pbRate":"1.87","psRate":"10.60","week52High":2.25,"institutionHeld":0,"latestPrice":0.8101,"committee":0.685039,"eps":-0.493118,"divideRate":0,"volume":134132,"delay":0,"ttmEps":-0.493118,"open":0.705,"prevYearClose":1,"prevWeekClose":0.7438,"prevMonthClose":0.5923,"prevQuarterClose":0.6501,"fiveDayClose":0.703,"twentyDayClose":0.5414,"sixtyDayClose":0.798},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTOR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"CTOR","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"post","actualEps":-0.08},{"market":"US","date":"2026-05-15","symbol":"CTOR","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2026-02-13","symbol":"CTOR","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1770958800000,"reportTimeType":"pre","actualEps":-0.06},{"market":"US","date":"2025-12-23","symbol":"CTOR","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1766466000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-08-12","symbol":"CTOR","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.08}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTOR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTOR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1758686400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTOR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTOR","date":"2026-08-25","current":-1.642812,"percent":0.880716,"low":-14.569058,"twenty":-5.385803,"median":-3.834182,"eighty":-2.306734,"high":-1.173027,"avg":-3.968078,"sd":1.954245,"marketCap":79319236},"quantilePoints":[{"date":"2024-08-23","current":-7.506449,"twenty":-8.175502,"median":-7.996,"eighty":-7.800179,"marketCap":131199450},{"date":"2024-08-30","current":-6.464428,"twenty":-8.028637,"median":-7.567643,"eighty":-6.639734,"marketCap":126208166},{"date":"2024-09-06","current":-6.847911,"twenty":-7.922567,"median":-7.149219,"eighty":-6.405992,"marketCap":133695091},{"date":"2024-09-13","current":-5.989639,"twenty":-7.726747,"median":-6.50095,"eighty":-6.274513,"marketCap":116938640},{"date":"2024-09-20","current":-6.099206,"twenty":-7.555404,"median":-6.464428,"eighty":-5.97503,"marketCap":119077761},{"date":"2024-09-27","current":-5.222673,"twenty":-7.472896,"median":-6.354861,"eighty":-5.953117,"marketCap":101964790},{"date":"2024-10-04","current":-4.309619,"twenty":-7.088957,"median":-6.190511,"eighty":-5.617113,"marketCap":84138777},{"date":"2024-10-11","current":-3.542653,"twenty":-6.749301,"median":-6.099206,"eighty":-5.018149,"marketCap":69164927},{"date":"2024-10-18","current":-3.944397,"twenty":-6.661648,"median":-5.953117,"eighty":-4.16353,"marketCap":77008372},{"date":"2024-10-25","current":-4.399098,"twenty":-6.559386,"median":-5.916595,"eighty":-4.331532,"marketCap":85885727},{"date":"2024-10-31","current":-4.419185,"twenty":-6.486341,"median":-5.66094,"eighty":-4.324228,"marketCap":86277899},{"date":"2024-11-08","current":-4.602892,"twenty":-6.464428,"median":-5.16789,"eighty":-4.287705,"marketCap":89864492},{"date":"2024-11-15","current":-3.904222,"twenty":-6.464428,"median":-4.930496,"eighty":-4.287705,"marketCap":76224028},{"date":"2024-11-22","current":-3.564201,"twenty":-6.420601,"median":-4.784407,"eighty":-3.944397,"marketCap":69585621},{"date":"2024-11-29","current":-3.356755,"twenty":-6.347557,"median":-4.693102,"eighty":-3.842134,"marketCap":65535551},{"date":"2024-12-06","current":-5.916595,"twenty":-6.296426,"median":-4.747885,"eighty":-3.776395,"marketCap":115512559},{"date":"2024-12-13","current":-3.907874,"twenty":-6.201468,"median":-4.620605,"eighty":-3.842134,"marketCap":76295332},{"date":"2024-12-20","current":-3.871352,"twenty":-6.164946,"median":-4.528752,"eighty":-3.842134,"marketCap":75582291},{"date":"2024-12-27","current":-3.50613,"twenty":-6.135728,"median":-4.435255,"eighty":-3.725263,"marketCap":68451887},{"date":"2025-01-03","current":-4.012144,"twenty":-6.10651,"median":-4.399098,"eighty":-3.717959,"marketCap":84851818},{"date":"2025-01-10","current":-3.992285,"twenty":-6.033466,"median":-4.399098,"eighty":-3.747177,"marketCap":84431834},{"date":"2025-01-17","current":-4.465946,"twenty":-5.967726,"median":-4.376046,"eighty":-3.723807,"marketCap":94449170},{"date":"2025-01-24","current":-4.296782,"twenty":-5.953117,"median":-4.35308,"eighty":-3.739872,"marketCap":90871550},{"date":"2025-01-31","current":-4.262949,"twenty":-5.953117,"median":-4.346141,"eighty":-3.761786,"marketCap":90156026},{"date":"2025-02-07","current":-4.026118,"twenty":-5.938508,"median":-4.309619,"eighty":-3.767526,"marketCap":85147358},{"date":"2025-02-14","current":-4.330615,"twenty":-5.916595,"median":-4.296782,"eighty":-3.799613,"marketCap":91587074},{"date":"2025-02-21","current":-3.72014,"twenty":-5.901986,"median":-4.296782,"eighty":-3.761786,"marketCap":85862882},{"date":"2025-02-28","current":-3.689139,"twenty":-5.807029,"median":-4.262949,"eighty":-3.720436,"marketCap":85147358},{"date":"2025-03-07","current":-3.162119,"twenty":-5.639027,"median":-4.229116,"eighty":-3.689139,"marketCap":72983450},{"date":"2025-03-14","current":-2.294087,"twenty":-5.507546,"median":-4.152992,"eighty":-3.653403,"marketCap":52948777},{"date":"2025-03-21","current":-1.891071,"twenty":-5.317631,"median":-4.127617,"eighty":-3.617985,"marketCap":43646965},{"date":"2025-03-28","current":-2.030577,"twenty":-5.251891,"median":-4.059951,"eighty":-3.565808,"marketCap":46866823},{"date":"2025-04-04","current":-2.191783,"twenty":-5.220193,"median":-4.053963,"eighty":-3.506186,"marketCap":50587548},{"date":"2025-04-11","current":-1.919282,"twenty":-5.198143,"median":-4.02178,"eighty":-3.38992,"marketCap":44298092},{"date":"2025-04-17","current":-2.002676,"twenty":-5.149629,"median":-4.014793,"eighty":-3.224122,"marketCap":46222851},{"date":"2025-04-25","current":-1.987175,"twenty":-5.113107,"median":-3.992285,"eighty":-3.104751,"marketCap":45865089},{"date":"2025-05-02","current":-2.759104,"twenty":-5.076585,"median":-3.944397,"eighty":-2.759104,"marketCap":63681637},{"date":"2025-05-09","current":-2.619599,"twenty":-4.930496,"median":-3.907874,"eighty":-2.693382,"marketCap":60461779},{"date":"2025-05-16","current":-2.437632,"twenty":-4.930496,"median":-3.890787,"eighty":-2.691522,"marketCap":63331031},{"date":"2025-05-23","current":-2.506208,"twenty":-4.784407,"median":-3.875146,"eighty":-2.619599,"marketCap":65112685},{"date":"2025-05-30","current":-2.451953,"twenty":-4.784407,"median":-3.871352,"eighty":-2.502848,"marketCap":63703103},{"date":"2025-06-06","current":-2.671453,"twenty":-4.755189,"median":-3.805483,"eighty":-2.487546,"marketCap":69405829},{"date":"2025-06-13","current":-4.04849,"twenty":-4.660231,"median":-3.776135,"eighty":-2.502848,"marketCap":105182030},{"date":"2025-06-20","current":-4.268817,"twenty":-4.617062,"median":-3.83483,"eighty":-2.506208,"marketCap":110906223},{"date":"2025-06-27","current":-9.639263,"twenty":-4.842843,"median":-3.873249,"eighty":-2.506208,"marketCap":250433407},{"date":"2025-07-03","current":-14.569058,"twenty":-5.098498,"median":-3.876214,"eighty":-2.511716,"marketCap":378512206},{"date":"2025-07-11","current":-8.950744,"twenty":-5.244587,"median":-3.890787,"eighty":-2.545647,"marketCap":232545306},{"date":"2025-07-18","current":-4.40652,"twenty":-5.303022,"median":-3.909331,"eighty":-2.598329,"marketCap":114483843},{"date":"2025-07-25","current":-5.370447,"twenty":-5.303022,"median":-3.944397,"eighty":-2.622079,"marketCap":139527183},{"date":"2025-08-01","current":-7.246465,"twenty":-5.617113,"median":-3.968341,"eighty":-2.631999,"marketCap":188267172},{"date":"2025-08-08","current":-6.066045,"twenty":-5.92757,"median":-3.993409,"eighty":-2.65122,"marketCap":157599217},{"date":"2025-08-15","current":-5.071831,"twenty":-5.92757,"median":-4.017441,"eighty":-2.668242,"marketCap":134797404},{"date":"2025-08-22","current":-4.806444,"twenty":-5.916595,"median":-4.026118,"eighty":-2.679481,"marketCap":127744051},{"date":"2025-08-29","current":-6.251327,"twenty":-5.92757,"median":-4.051227,"eighty":-2.692266,"marketCap":166145638},{"date":"2025-09-05","current":-5.514142,"twenty":-5.933303,"median":-4.056957,"eighty":-2.700326,"marketCap":146552992},{"date":"2025-09-12","current":-5.938837,"twenty":-5.933303,"median":-4.063335,"eighty":-2.734303,"marketCap":157840405},{"date":"2025-09-19","current":-5.498923,"twenty":-5.933303,"median":-4.134553,"eighty":-2.759104,"marketCap":146148523},{"date":"2025-09-26","current":-5.71888,"twenty":-5.924891,"median":-4.16145,"eighty":-2.75929,"marketCap":151994464},{"date":"2025-10-03","current":-5.907415,"twenty":-5.938047,"median":-4.221426,"eighty":-2.76177,"marketCap":157005270},{"date":"2025-10-10","current":-5.750303,"twenty":-5.938047,"median":-4.262949,"eighty":-2.769272,"marketCap":152829598},{"date":"2025-10-17","current":-5.624613,"twenty":-5.934887,"median":-4.265883,"eighty":-2.785269,"marketCap":149489061},{"date":"2025-10-24","current":-5.247544,"twenty":-5.933303,"median":-4.296782,"eighty":-2.845783,"marketCap":139467448},{"date":"2025-10-31","current":-5.436079,"twenty":-5.924891,"median":-4.3032,"eighty":-2.870708,"marketCap":144478254},{"date":"2025-11-07","current":-4.524828,"twenty":-5.916595,"median":-4.309619,"eighty":-2.884898,"marketCap":120259356},{"date":"2025-11-14","current":-4.179182,"twenty":-5.914759,"median":-4.309619,"eighty":-2.896465,"marketCap":111072877},{"date":"2025-11-21","current":-3.550733,"twenty":-5.907415,"median":-4.304871,"eighty":-2.952238,"marketCap":94370189},{"date":"2025-11-28","current":-4.304871,"twenty":-5.907415,"median":-4.296782,"eighty":-3.104751,"marketCap":114413415},{"date":"2025-12-05","current":-3.487889,"twenty":-5.875992,"median":-4.296782,"eighty":-3.112056,"marketCap":92699920},{"date":"2025-12-12","current":-3.550733,"twenty":-5.86799,"median":-4.273096,"eighty":-3.162119,"marketCap":94370189},{"date":"2025-12-19","current":-3.582156,"twenty":-5.84457,"median":-4.262949,"eighty":-3.19281,"marketCap":95205323},{"date":"2025-12-26","current":-3.92117,"twenty":-5.843755,"median":-4.262949,"eighty":-3.21786,"marketCap":97093533},{"date":"2026-01-02","current":-3.424602,"twenty":-5.82283,"median":-4.235196,"eighty":-3.269261,"marketCap":84797846},{"date":"2026-01-09","current":-3.869801,"twenty":-5.792641,"median":-4.210604,"eighty":-3.333795,"marketCap":95821565},{"date":"2026-01-16","current":-3.698571,"twenty":-5.781725,"median":-4.16249,"eighty":-3.356755,"marketCap":91581673},{"date":"2026-01-23","current":-3.835555,"twenty":-5.769156,"median":-4.143012,"eighty":-3.358933,"marketCap":94973587},{"date":"2026-01-30","current":-3.921541,"twenty":-5.737734,"median":-4.109523,"eighty":-3.368971,"marketCap":97102724},{"date":"2026-02-06","current":-3.957191,"twenty":-5.706311,"median":-4.080473,"eighty":-3.382482,"marketCap":97985476},{"date":"2026-02-13","current":-4.206744,"twenty":-5.687458,"median":-4.063335,"eighty":-3.402348,"marketCap":104164740},{"date":"2026-02-20","current":-4.519036,"twenty":-5.682154,"median":-4.084915,"eighty":-3.42469,"marketCap":106812996},{"date":"2026-02-27","current":-4.070867,"twenty":-5.656708,"median":-4.104658,"eighty":-3.426652,"marketCap":96219972},{"date":"2026-03-06","current":-3.996173,"twenty":-5.636748,"median":-4.084915,"eighty":-3.433086,"marketCap":94454468},{"date":"2026-03-13","current":-3.398614,"twenty":-5.624613,"median":-4.070867,"eighty":-3.433086,"marketCap":80330435},{"date":"2026-03-20","current":-2.579959,"twenty":-5.624613,"median":-4.059951,"eighty":-3.389732,"marketCap":60980510},{"date":"2026-03-27","current":-2.020495,"twenty":-5.620211,"median":-4.053963,"eighty":-3.356755,"marketCap":47756885},{"date":"2026-04-02","current":-2.420485,"twenty":-5.602604,"median":-4.04849,"eighty":-3.19281,"marketCap":57211159},{"date":"2026-04-10","current":-2.464929,"twenty":-5.593191,"median":-4.028492,"eighty":-3.034103,"marketCap":58261634},{"date":"2026-04-17","current":-3.007213,"twenty":-5.593191,"median":-4.027305,"eighty":-2.91411,"marketCap":71079194},{"date":"2026-04-24","current":-3.65183,"twenty":-5.573117,"median":-4.02207,"eighty":-3.007213,"marketCap":86315494},{"date":"2026-05-01","current":-3.286198,"twenty":-5.551373,"median":-4.014793,"eighty":-3.009828,"marketCap":77673351},{"date":"2026-05-08","current":-3.364628,"twenty":-5.543629,"median":-3.993409,"eighty":-3.034103,"marketCap":79527131},{"date":"2026-05-15","current":-3.676105,"twenty":-5.530346,"median":-3.975555,"eighty":-3.099835,"marketCap":86889283},{"date":"2026-05-22","current":-1.721465,"twenty":-5.514142,"median":-3.957191,"eighty":-2.91411,"marketCap":73180144},{"date":"2026-05-29","current":-1.674951,"twenty":-5.514142,"median":-3.944397,"eighty":-2.880009,"marketCap":71202779},{"date":"2026-06-05","current":-1.652731,"twenty":-5.501967,"median":-3.944397,"eighty":-2.770947,"marketCap":70258234},{"date":"2026-06-12","current":-1.438015,"twenty":-5.498923,"median":-3.938293,"eighty":-2.752904,"marketCap":61130578},{"date":"2026-06-18","current":-1.370943,"twenty":-5.498923,"median":-3.927802,"eighty":-2.683494,"marketCap":58279289},{"date":"2026-06-26","current":-1.443591,"twenty":-5.48007,"median":-3.921541,"eighty":-2.625689,"marketCap":61367594},{"date":"2026-07-02","current":-1.540487,"twenty":-5.454932,"median":-3.92117,"eighty":-2.581635,"marketCap":65486661},{"date":"2026-07-10","current":-1.57767,"twenty":-5.436079,"median":-3.907874,"eighty":-2.528121,"marketCap":67067342},{"date":"2026-07-17","current":-1.491711,"twenty":-5.431919,"median":-3.890787,"eighty":-2.506208,"marketCap":63413181},{"date":"2026-07-24","current":-1.264673,"twenty":-5.422175,"median":-3.877282,"eighty":-2.478998,"marketCap":53761732},{"date":"2026-07-31","current":-1.255049,"twenty":-5.414466,"median":-3.875146,"eighty":-2.461623,"marketCap":53352614},{"date":"2026-08-07","current":-1.662317,"twenty":-5.404656,"median":-3.870576,"eighty":-2.451127,"marketCap":70665715},{"date":"2026-08-14","current":-1.808426,"twenty":-5.404656,"median":-3.869801,"eighty":-2.413051,"marketCap":76876859},{"date":"2026-08-21","current":-1.532251,"twenty":-5.398372,"median":-3.835192,"eighty":-2.327137,"marketCap":70582031},{"date":"2026-08-25","current":-1.721926,"twenty":-5.385803,"median":-3.834182,"eighty":-2.306734,"marketCap":79319236}],"updateTime":1787736674733},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTOR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659124449","title":"Citius Oncology Files Form 3 for Director Jonathan Peri","url":"https://stock-news.laohu8.com/highlight/detail?id=2659124449","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659124449?lang=en_us&edition=fundamental","pubTime":"2026-08-15 06:00","pubTimestamp":1786744807,"startTime":"0","endTime":"0","summary":"Citius Oncology files Form 3 for director Jonathan PeriCitius Oncology director Jonathan Peri filed an initial Form 3 ownership disclosure dated 08/10/2026.Disclaimer:This news brief was created by Pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL6rD2dp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTXR","CTOR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659797121","title":"Citius Oncology Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659797121","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659797121?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:08","pubTimestamp":1786741709,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc reports results for the quarter ended June 30 - Earnings SummaryCitius Oncology IncCTOR.OQreported a quarterly adjusted loss of 8 cents per share for the quarter ended June 30, ide","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B1M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4139","BK4007","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659712115","title":"Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659712115","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659712115?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:58","pubTimestamp":1786741089,"startTime":"0","endTime":"0","summary":"Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year.  The company reported quarterly sales of $1.494","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61230966/citius-oncology-q3-eps-0-08-inline-sales-1-494m-miss-2-500m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659292881","title":"Citius Oncology FY26 Q3 Net Loss Widens to $8.9 Million; Revenue Rises to $1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659292881","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659292881?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:31","pubTimestamp":1786739486,"startTime":"0","endTime":"0","summary":"Citius Oncology FY26 Q3 net loss widens to $8.9 million; revenue rises to $1.5 millionCitius Oncology posted revenue of USD 1.49 million for fiscal Q3 ended June 30, 2026, versus no revenue a year ear","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL93kZww:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","CTOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659912921","title":"Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659912921","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659912921?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:30","pubTimestamp":1786739400,"startTime":"0","endTime":"0","summary":"$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR (R)$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","R","ORR","CTXR","FXN","BK4007","BK4022","BK4139","PR","CTOR","CR","BK4161","BK4232","PXI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129230","title":"Press Release: Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129230","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129230?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:30","pubTimestamp":1786739400,"startTime":"0","endTime":"0","summary":"$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR(R) launch progressesStrong institutional demand drives growth in total vials ordered and number of institutions ordering","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DT","LU1169589451.USD","BK4022","BK4232","BK4139","BK4213","CTOR","BK4007","BK4555","CTXR","BK4023","LU1169590202.USD","TM","ORR","PXI","LU0348723411.USD","FXN","BK4585","BK4588","BK4560","BK4161","BK4099","03160","CR","PR","BK4604","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972976","title":"Citius Oncology Appoints Jonathan Peri as Independent Director, Expands Board to Nine Members","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972976","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972976?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:06","pubTimestamp":1786536405,"startTime":"0","endTime":"0","summary":"Citius Oncology appoints Jonathan Peri as independent director, expands board to nine membersCitius Oncology appointed Jonathan Peri as an independent director, effective Aug. 10, expanding the board ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL5fDSrj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTXR","BK4007","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997253","title":"Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997253","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997253?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA79MTNB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTOR","BK4007","CTXR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657642879","title":"Citius Oncology Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657642879","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657642879?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:45","pubTimestamp":1786113908,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc <CTOR.OQ> expected to post a loss of5cents a share - Earnings PreviewCitius Oncology IncCTOR.OQCTOR.Ois expected to  show a rise in quarterly revenue when it reports  results on August 10  for the period ending June 30 2026The Cranford New Jersey-based  company is expected to report revenue of $5.831 million, according to the estimate from one analyst, based on LSEG data.LSEG's mean analyst estimate for Citius Oncology Inc is for a loss of 5 cents per share.The one available analyst rating on the shares is \"buy\".The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Citius Oncology Inc is $4.00, about 426.3% above its last closing price of $0.76This summary was machine generated August 7 at 14:45 GMT.  All figures in US dollars unless otherwise stated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4007","BK4139","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540857","title":"Citius Pharma Subsidiary Citius Oncology Says New Lymphir Institutional Accounts Jump 78% Q/Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540857","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657540857?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:27","pubTimestamp":1785936477,"startTime":"0","endTime":"0","summary":"Citius Pharma subsidiary Citius Oncology says new LYMPHIR institutional accounts jump 78% Q/QCitius Pharma’s majority-owned unit Citius Oncology reported faster early uptake for LYMPHIR in cutaneous T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL9sxZzV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTOR","CTXR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547243","title":"Citius Oncology Reports Strong Commercial Momentum for Its Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657547243?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:17","pubTimestamp":1785935820,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA2C95FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTXR","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653520338","title":"Citius Oncology provides update on commercial launch of Lymphir","url":"https://stock-news.laohu8.com/highlight/detail?id=2653520338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653520338?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:25","pubTimestamp":1784640339,"startTime":"0","endTime":"0","summary":"Citius Oncology (CTOR), majority-owned subsidiary of Citius Pharmaceuticals (CTXR), provided an update on the commercial launch of Lymphir – denile...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-oncology-provides-update-on-commercial-launch-of-lymphir-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-oncology-provides-update-on-commercial-launch-of-lymphir-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTXR","BK4007","CTOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951690","title":"Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951690","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951690?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:16","pubTimestamp":1780316212,"startTime":"0","endTime":"0","summary":"Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), highlighted Phase 1 clinical data presented May 30 at the Ame...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-oncology-highlights-phase-1-data-evaluating-lymphir-at-asco-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-oncology-highlights-phase-1-data-evaluating-lymphir-at-asco-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTOR","BK4139","BK4007","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640695527","title":"Citius Oncology highlights Phase 1 study data for LYMPHIR-pembrolizumab combo in recurrent gynecologic cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2640695527","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640695527?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:05","pubTimestamp":1780311902,"startTime":"0","endTime":"0","summary":"Citius Oncology highlighted Phase 1 data already presented May 30, 2026, at ASCO for LYMPHIR combined with pembrolizumab in recurrent gynecologic cancers.Study showed durable tumor shrinkage in some heavily pre-treated patients, including those who had already failed prior immunotherapy.Safety profile appeared manageable, with serious side effects concentrated at the highest dose level.Results support a planned Phase 2 expansion to test the regimen in broader gynecologic cancer populations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via PR Newswire  on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL2QcXZm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTXR","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639677771","title":"Citius Oncology shareholders OK stock issuance tied to USD 25 million loan conversion option","url":"https://stock-news.laohu8.com/highlight/detail?id=2639677771","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639677771?lang=en_us&edition=fundamental","pubTime":"2026-05-30 05:02","pubTimestamp":1780088564,"startTime":"0","endTime":"0","summary":"Citius Oncology board resolutions dated May 5 set up stock issuance tied to a new Loan Agreement, later ratified by majority written consent on May 22.Written consent cleared share issuance for lenders’ conversion option on up to USD 4 million loan principal at USD 1.08 per share.Consent also authorized stock issuance on exercise of lender warrants, sized off USD 1 million value and 10% of funded later tranches at USD 0.9.Stockholder action approved issuance on May 2026 inducement warrants for 25,555,556 shares at USD 0.9, placement-agent warrants for 894,444 shares at USD 1.13.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLKxQTg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CTXR","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638141075","title":"Citius Oncology to present Phase 1 LYMPHIR-pembrolizumab combo data at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638141075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638141075?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:15","pubTimestamp":1779797715,"startTime":"0","endTime":"0","summary":"Citius Oncology flagged a Phase 1 study of LYMPHIR with Merck’s Keytruda for poster presentation at ASCO 2026.Results will be presented May 30, 2026; the study tested the combination in relapsed or refractory gynecologic cancers.Top-line findings showed signs of tumor shrinkage in some patients, with responses that tended to last, supporting further development interest.Safety signals were described as favorable, supporting the strategy of using LYMPHIR to potentially boost checkpoint inhibitor activity beyond CTCL.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL35Vxd9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CTXR","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636219864","title":"Citius Oncology files draft information statement on warrant, loan conversion share issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2636219864","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636219864?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:31","pubTimestamp":1779222676,"startTime":"0","endTime":"0","summary":"Shareholders authorized share issuance tied to a new term-loan facility of up to USD 25 million, including stock issuable if lenders convert up to USD 4 million of outstanding loan principal at USD 1.08 per share.The authorization also covers shares underlying lender warrants with a USD 0.90 exercise price, sized to USD 1 million of warrant value with additional warrant value linked to any funded Tranche 2 or Tranche 3 borrowings.Additional share issuance was authorized for warrants issued in May, including May Common Warrants for 25,555,556 shares at USD 0.90, May PA Warrants for 894,444 shares at USD 1.125.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news br","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDLbPVtYy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","CTXR","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635053194","title":"Citius Oncology Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635053194","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635053194?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:46","pubTimestamp":1778881619,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc reports results for the quarter ended March 31 - Earnings SummaryCitius Oncology Inc CTOR.OQ reported a quarterly adjusted loss of $1.43 per share for the quarter ended March 31, l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S28E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","CTOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635030623","title":"Citius Oncology FY26 Q2 net loss widens to $26.6 million; revenue rises to $1.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030623","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030623?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:31","pubTimestamp":1778877101,"startTime":"0","endTime":"0","summary":"Citius Oncology posted fiscal Q2 net loss of $26.6 million, widening from $7.7 million year-earlier; net product revenues rose to $1.7 million from no revenue.G&A expenses climbed to $23.6 million from $2.2 million, driven by a $19.7 million one-time CMO contract cancellation charge.Gross profit came in at $1.3 million, implying an 80% margin; cash and cash equivalents totaled $2.6 million at quarter end.Subsequent to quarter end, up to $36.5 million in debt and equity capital was secured, including $11.5 million in warrant exercise proceeds plus a $25 million senior secured term loan facility with $10 million funded at close.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to gen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL8kHqVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTXR","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635985030","title":"Press Release: Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635985030","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635985030?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:30","pubTimestamp":1778877000,"startTime":"0","endTime":"0","summary":"$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR launch progresses. Up to $36.5 million in debt and equity capital secured. Broad payer coverage established with no reimbursement denials. \"Building on the commercial foundation we are establishing in the U.S., we have initiated our first European shipment as part of the international distribution agreements we have in place across 19 markets in Southern Europe, the Middle East, and additional Western and Eastern European territories. At the same time, we continue to strengthen LYMPHIR's long-term value proposition","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","CTXR","BK4139","BK4007","CTOR","BK4022","R"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}